Glaukos’ phase 3 confirmatory trial for Epioxa reaches pipeline enrollment milestoneJune 5th 2023
The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.
Bausch + Lomb celebrates US launch of Infuse Multifocal SiHy daily disposable contact lensesJune 5th 2023
Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses leverage Bausch + Lomb’s proprietary lens tech to deliver all-day comfort and seamless transitions between near, intermediate, and distance vision for patients with presbyopia.
AI used to advance drug delivery system for glaucoma and other chronic diseasesJune 2nd 2023
The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.
New FDA blood donor recommendations could ease restrictions on cornea donations from queer menJune 1st 2023
The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities—such as transgender women or nonbinary donors—will be impacted.
Genentech, American Diabetes Association partner to improve access to screening and treatment for diabetic eye diseaseMay 26th 2023
As part of the American Diabetes Association's Health Equity Now program, the organization has partnered with Genentech, piloting a partnership within Alabama to specifically focusing on tackling barriers related to diabetic eye disease.